Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosn, Marwan, Dagher, Alain, El-Karak, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585438/
https://www.ncbi.nlm.nih.gov/pubmed/26442650
http://dx.doi.org/10.7555/JBR.28.20130148
_version_ 1782392207048704000
author Ghosn, Marwan
Dagher, Alain
El-Karak, Fadi
author_facet Ghosn, Marwan
Dagher, Alain
El-Karak, Fadi
author_sort Ghosn, Marwan
collection PubMed
description We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
format Online
Article
Text
id pubmed-4585438
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial Department of Journal of Biomedical Research
record_format MEDLINE/PubMed
spelling pubmed-45854382015-10-06 Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient Ghosn, Marwan Dagher, Alain El-Karak, Fadi J Biomed Res Case Report We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient. Editorial Department of Journal of Biomedical Research 2015-09 2014-03-30 /pmc/articles/PMC4585438/ /pubmed/26442650 http://dx.doi.org/10.7555/JBR.28.20130148 Text en © 2015 by the Journal of Biomedical Research. All rights reserved.
spellingShingle Case Report
Ghosn, Marwan
Dagher, Alain
El-Karak, Fadi
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title_full Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title_fullStr Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title_full_unstemmed Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title_short Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
title_sort prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585438/
https://www.ncbi.nlm.nih.gov/pubmed/26442650
http://dx.doi.org/10.7555/JBR.28.20130148
work_keys_str_mv AT ghosnmarwan prostatespecificantigendoublingtimeandresponsetocabazitaxelinahormoneresistantmetastaticprostatecancerpatient
AT dagheralain prostatespecificantigendoublingtimeandresponsetocabazitaxelinahormoneresistantmetastaticprostatecancerpatient
AT elkarakfadi prostatespecificantigendoublingtimeandresponsetocabazitaxelinahormoneresistantmetastaticprostatecancerpatient

Ejemplares similares